Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 15/20 | 0.72 |
| ▸ | MAPK12 | P53778 | 12/20 | 0.72 |
| ▸ | HCK | P08631 | 10/20 | 0.68 |
| ▸ | SRC | P12931 | 7/20 | 0.68 |
| ▸ | GSK3A | P49840 | 5/20 | 0.68 |
| ▸ | SYK | P43405 | 4/20 | 0.68 |
| ▸ | GSK3B | P49841 | 1/20 | 0.68 |
| ▸ | BRAF | P15056 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13504135 | 0.93 | MAPK14 (0.77) | MAPK14MAPK12HCKSRCGSK3A | |
| SCHEMBL2527570 | 0.93 | MAPK14 (0.81) | MAPK14MAPK12HCKSRCGSK3A | |
| SCHEMBL12540421 | 0.92 | MAPK14 (0.77) | MAPK14MAPK12HCKSRCGSK3A | |
| SCHEMBL16240690 | 0.92 | MAPK14 (0.79) | MAPK14MAPK12HCKSRCGSK3A | |
| SCHEMBL14687952 | 0.90 | MAPK14 (0.70) | MAPK14MAPK12HCKSRCGSK3A | |
| SCHEMBL1694481 | 0.90 | MAPK14 (0.76) | MAPK14MAPK12HCKSRCGSK3A | |
| SCHEMBL20060690 | 0.88 | MAPK14 (0.56) | MAPK14MAPK12HCKSRCGSK3A | |
| SCHEMBL14688220 | 0.88 | MAPK14 (0.72) | MAPK14MAPK12HCKSRCGSK3A | |
| SCHEMBL13504156 | 0.87 | MAPK14 (0.67) | MAPK14MAPK12HCKSRCGSK3A | |
| SCHEMBL16239870 | 0.86 | MAPK12 (0.68) | MAPK14MAPK12HCKSRCGSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2370429-B1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD (GB) | 2016-04-20 | — | — | EP | claimed |
| US-20130123260-A1 | Methods | RESPIVERT LIMITED (GB) | 2013-05-16 | — | — | US | claimed |
| EP-2582433-A2 | METHODS | Respivert Limited (GB) | 2013-04-24 | — | — | EP | claimed |
| US-8299073-B2 | P38 MAP kinase inhibitors | RESPIVERT LTD. (GB) | 2012-10-30 | — | — | US | claimed |
| US-8299074-B2 | P38 MAP kinase inhibitors | RESPIVERT LTD. (GB) | 2012-10-30 | — | — | US | claimed |
| WO-2011158042-A2 | METHODS | RESPIVERT LIMITED (GB) | 2011-12-22 | — | — | WO | claimed |
| US-20110312963-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD (GB) | 2011-12-22 | — | — | US | claimed |
| US-20110294812-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD. (GB) | 2011-12-01 | — | — | US | claimed |
| EP-2582433-B1 | UREIDO-PYRAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF RHINOVIRUS INFECTIONS | RESPIVERT LTD (GB) | 2018-04-18 | — | — | EP | disclosed |
| EP-2509595-B1 | INHIBITORS OF HEMOPOIETIC CELL KINASE (P59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTION | RESPIVERT LTD (GB) | 2018-04-11 | — | — | EP | disclosed |
| US-20180000830-A1 | INHIBITORS OF HEMOPOIETIC CELL KINASE (P-59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTION | RESPIVERT LIMITED (GB) | 2018-01-04 | — | — | US | disclosed |
| EP-2370429-B1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD (GB) | 2016-04-20 | — | — | EP | disclosed |
| US-20160045482-A1 | UREIDO-PYRAZOLE DERIVATIVES | RESPIVERT LIMITED (GB) | 2016-02-18 | — | — | US | disclosed |
| US-20160045512-A1 | Inhibitors of Hemopoietic Cell Kinase (P59-HCK) and Their Use in the Treatment of Influenza Infection | RESPIVERT LIMITED (GB) | 2016-02-18 | — | — | US | disclosed |
| US-20130102607-A1 | UREIDO-PYRAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF RHINOVIRUS INFECTIONS | RESPIVERT LIMITED (US) | 2013-04-25 | — | — | US | disclosed |
| US-8299073-B2 | P38 MAP kinase inhibitors | RESPIVERT LTD. (GB) | 2012-10-30 | — | — | US | disclosed |
| US-8299074-B2 | P38 MAP kinase inhibitors | RESPIVERT LTD. (GB) | 2012-10-30 | — | — | US | disclosed |
| US-20120244120-A1 | INHIBITORS OF HEMOPOIETIC CELL KINASE (P59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTION | RESPIVERT LTD. (GB) | 2012-09-27 | — | — | US | disclosed |
| US-20110312963-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD (GB) | 2011-12-22 | — | — | US | disclosed |
| US-20110294812-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD. (GB) | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312963-A1 | P38 MAP KINASE INHIBITORS | MAPKAPK2, MAPK1, MAPKAPK3 | MAPK14 25/4885MAPK12 34/4885HCK 1150/4885 |
| US-20180000830-A1 | INHIBITORS OF HEMOPOIETIC CELL KINASE (P-59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTION | HCK, CDK9, PHKG1 | MAPK14 257/4885MAPK12 621/4885HCK 1/4885 |
| US-20160045482-A1 | UREIDO-PYRAZOLE DERIVATIVES | CFTR, URB2, PRPF3 | MAPK14 3343/4885MAPK12 3951/4885HCK 4458/4885 |
| US-20120244120-A1 | INHIBITORS OF HEMOPOIETIC CELL KINASE (P59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTION | HCK, CDK9, TTK | MAPK14 418/4885MAPK12 634/4885HCK 1/4885 |
| US-20110294812-A1 | P38 MAP KINASE INHIBITORS | MAPK1, MAP3K1, MAPK3 | MAPK14 10/4885MAPK12 13/4885HCK 348/4885 |
| US-20130123260-A1 | Methods | CFTR, SERPINB1, CMA1 | MAPK14 3580/4885MAPK12 3675/4885HCK 3923/4885 |
| US-20130102607-A1 | UREIDO-PYRAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF RHINOVIRUS INFECTIONS | URB2, RPL35, PRPF3 | MAPK14 3791/4885MAPK12 3947/4885HCK 4717/4885 |
| US-20160045512-A1 | Inhibitors of Hemopoietic Cell Kinase (P59-HCK) and Their Use in the Treatment of Influenza Infection | HCK, CDK9, TTK | MAPK14 418/4885MAPK12 634/4885HCK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.